Allocetra

Cell therapy

Phase 2topline reported

Evidence outlook

Osteoarthritis: topline reported 2025-08-18

The sponsor reported topline results on 2025-08-18 (Phase IIa stage of ENX-CL-05-001 (NCT06233474): positive three-month topline data in knee osteoarthritis). The announcement is listed under Regulatory events.

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (4)
Osteoarthritis
NCT07580716 · Enlivex Therapeutics Ltd.
2026-05-01 – 2028-04 · Primary Knee Osteoarthritis
What this study did
Other / comorbidity
NCT04612413 · Enlivex Therapeutics Ltd.
2020-11-30 – 2024-12-16 · Sepsis, Community-acquired Pneumonia, Urinary Tract Infections, Cholecystitis, Acute, Cholangitis Acute, Intraabdominal Infections
What this study did
NCT04590053 · Hadassah Medical Organization
2020-10-20 – 2021-03 · Covid19
What this study did
Phase 1/2 (4)
Osteoarthritis
NCT06459063 · Kaplan Medical Center
2024-06-10 – 2027-01 · Osteoarthritis Thumb
What this study did
Other / comorbidity
NCT05581719 · Enlivex Therapeutics RDO Ltd.
2022-11-15 – 2024-04-15 · Solid Tumor, Peritoneal Metastases, Peritoneal Cancer
What this study did
Phase 1 (6)
Osteoarthritis
NCT06208241 · Amir Oron
2023-07-12 – 2026-12-30 · Knee Osteoarthritis
What this study did
NCT06748651 · Dr. Amit Druyan
2024-12-15 – 2026-04-08 · Temporomandibular Joint Osteoarthritis
What this study did
Other / comorbidity
NCT06522035 · Enlivex Therapeutics Ltd.
2024-08-01 – 2026-04-08 · Arthritis, Psoriatic
What this study did
NCT04659304 · Enlivex Therapeutics Ltd.
2021-12 – 2022-12 · Covid19
What this study did
NCT04513470 · Hadassah Medical Organization
2020-08-01 – 2021-02 · COVID-19
What this study did
NCT03925857 · Enlivex Therapeutics Ltd.
2019-01-27 – 2020-01-12 · Organ Dysfunction Syndrome Sepsis
What this study did

Competitive landscape

This drug's own stage for Osteoarthritis: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Allocetra: this drugPhase 2Cell therapyMacrophage reprogrammingnot yet gradedNo reviewed efficacy summary in this indication
EcnoglutidePhase 3PeptideGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
EloralintidePhase 3PeptideAmylin receptornot yet gradedNo reviewed efficacy summary in this indication
Orforglipron (Foundayo)Phase 3Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
VutiglabridinPhase 2Small moleculeparaoxonase-2 (PON2)not yet gradedNo reviewed efficacy summary in this indication
PLX-PAD
—(overall)
Cell therapyMesenchymal stem cells (immunomodulatory, pro-angiogenic)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Allocetra to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
February 2027 (1)
Phase 2OsteoarthritisRecruiting
Est. primary completion 2027-02 · NCT07580716 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

18 August 2025Topline resultPhase IIa stage of ENX-CL-05-001 (NCT06233474): positive three-month topline data in knee osteoarthritis
Enlivex Therapeutics · Source ↗